Clinical trials recruiting for Metastatic Pancreatic Adenocarcinoma
10
Recruiting trials
41
US states with sites
3
Countries
10%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Fluorouracil | 4 |
| Gemcitabine | 4 |
| Irinotecan | 3 |
| Leucovorin | 3 |
| Nab-paclitaxel | 3 |
| Oxaliplatin | 2 |
| Cisplatin | 1 |
| Durvalumab | 1 |
| Glufosfamide | 1 |
| Imzokitug | 1 |
| Irinotecan Sucrosofate | 1 |
| Ligritinib | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 7 |
| Florida | 5 |
| Ohio | 4 |
| Arizona | 3 |
| Kentucky | 3 |
| Michigan | 3 |
| Minnesota | 3 |
| Missouri | 3 |
| Pennsylvania | 3 |
| Texas | 3 |
| Arkansas | 2 |
| Connecticut | 2 |
Top cities
Houston, Texas 3Irvine, California 3Sacramento, California 3St Louis, Missouri 3Atlanta, Georgia 2Baltimore, Maryland 2Billings, Montana 2Columbus, Ohio 2Duarte, California 2Fairfax, Virginia 2
Self-screener
Recruiting trials
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
- BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
- Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
- Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
- TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
- Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Related conditions
Trials recruiting for Metastatic Pancreatic Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Stage IV Pancreatic Cancer AJCC v8 19Stage III Pancreatic Cancer AJCC v8 14Unresectable Pancreatic Adenocarcinoma 4Unresectable Malignant Solid Neoplasm 8Metastatic Malignant Solid Neoplasm 21Locally Advanced Pancreatic Adenocarcinoma 16Stage II Pancreatic Cancer AJCC v8 9Pancreatic Ductal Adenocarcinoma 64Metastatic Pancreatic Cancer 26
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Metastatic Pancreatic Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.